Your trusted destination for CME, CPD & Medical Education across the Middle East.
Halia Therapeutics
Dr. David Bearss is a scientist, biotechnology entrepreneur and drug-development executive with more than two decades of experience in pharmaceutical research. He currently serves as CEO of Halia Therapeutics, where he leads development of therapies targeting chronic inflammation, neurodegeneration and related diseases. He has co-founded multiple biotechnology companies and has advanced numerous compounds from discovery through clinical development. Earlier in his career, he held academic positions at the University of Utah and Brigham Young University and worked at Tolero Pharmaceuticals and other biotechnology companies. His expertise includes structure-based drug discovery, cancer biology and translational therapeutics.
Dr. David J. Bearss is an American scientist, biotechnology entrepreneur, and pharmaceutical executive with extensive experience in drug discovery, cancer research, and pharmaceutical development. He is known for founding biotechnology companies, advancing experimental medicines into clinical development, and translating scientific discoveries into potential treatments for serious diseases.
Dr. Bearss earned his bachelor's degree from Brigham Young University and his Ph.D. in Cell Biology from the University of Texas Health Science Center at San Antonio. He subsequently completed postdoctoral training in oncology and drug development, developing expertise in cancer biology, molecular pharmacology, and translational research.
In 2003, Dr. Bearss founded Montigen Pharmaceuticals, a biotechnology company focused on drug discovery and development. The company was acquired by SuperGen Inc. in 2006. Following the acquisition, he held scientific leadership positions, including Chief Scientific Officer, where he contributed to early-stage pharmaceutical research and the advancement of potential drug candidates.
Dr. Bearss also pursued an academic career at the University of Utah and Brigham Young University. At the University of Utah's Huntsman Cancer Institute, he helped establish the Center for Investigational Therapeutics and served as its founding co-director. His academic work focused on oncology, therapeutic development, and collaboration between laboratory researchers and clinical investigators.
In 2011, he co-founded Tolero Pharmaceuticals and became its Chief Executive Officer. Under his leadership, the company developed experimental treatments for cancer and other serious diseases. Tolero was acquired by Sumitomo Dainippon Pharma in 2017 in a transaction reported to have a potential value of approximately US$780 million, including milestone payments. The acquisition represented a significant milestone in his biotechnology career.
Dr. Bearss later co-founded Halia Therapeutics, a biotechnology company focused on developing treatments for chronic inflammation, neurodegenerative diseases, and other serious medical conditions. He joined the company as Chief Scientific Officer in January 2021 and became President and Chief Executive Officer in March 2022.
At Halia Therapeutics, his work has focused on translating discoveries in inflammation biology and genetic resilience into potential therapies. The company's research programs have included investigations into myelodysplastic syndromes, Alzheimer's disease, and inflammatory disorders.
Throughout his career, Dr. Bearss has been involved in founding or co-founding multiple biotechnology companies and advancing experimental compounds into clinical development. His professional achievements have been recognized within Utah's biotechnology industry, including recognition associated with the Utah Governor's Medal of Science and BIO Utah's Entrepreneur of the Year award.
His career combines scientific research, pharmaceutical development, academic leadership, and biotechnology entrepreneurship, with a continuing focus on discovering and developing potential treatments for cancer and other serious diseases.
Early Career — Academic and Scientific Training
2003 — Founded Montigen Pharmaceuticals
2006 — Montigen Pharmaceuticals Acquired
2000s — Scientific Leadership at SuperGen
2000s–2010s — Academic Leadership
2011 — Co-Founded Tolero Pharmaceuticals
2011–2017 — Advanced Pharmaceutical Development
2017 — Tolero Pharmaceuticals Acquisition
January 2021 — Joined Halia Therapeutics
March 2022 — Became President and CEO of Halia Therapeutics
2022–2024 — Expanded Research Programs
2023 — Biotechnology Industry Recognition
2025 — Continued Drug Discovery Leadership
2026 — Continued Biotechnology Entrepreneurship
1. Founder of Montigen Pharmaceuticals — Established a biotechnology company focused on drug discovery and development.
2. Co-Founder and CEO of Tolero Pharmaceuticals — Built and led a pharmaceutical company developing experimental treatments for cancer and other serious diseases.
3. Tolero Pharmaceuticals Acquisition in 2017 — Led the company through its acquisition by Sumitomo Dainippon Pharma in a transaction with a reported potential value of approximately US$780 million, including milestone payments.
4. Co-Founder of Multiple Biotechnology Companies — Has founded or co-founded eight biotechnology companies, according to professional biographies.
5. Advancement of Drug Candidates — Has contributed to moving numerous experimental compounds from laboratory discovery into clinical development.
6. Utah Governor's Medal of Science — Listed in professional biographies among his recognitions for scientific and entrepreneurial contributions.
7. BIO Utah Entrepreneur of the Year — Recognized for contributions to biotechnology entrepreneurship.
8. Extensive Patent Portfolio — Earlier professional profiles credited him with more than 75 patents.
9. Founding Co-Director of the Center for Investigational Therapeutics — Helped establish a center dedicated to accelerating translational research and therapeutic development.
10. Leadership at Halia Therapeutics — Leads research and development programs involving chronic inflammation, neurodegeneration, and potential treatments for serious diseases.
Halia Therapeutics
Position: Co-Founder, President, and Chief Executive Officer.
Focus: Chronic inflammation, neurodegeneration, genetic resilience, and drug development.
Tolero Pharmaceuticals
Position: Co-Founder and former Chief Executive Officer.
Focus: Oncology, pharmaceutical development, and experimental therapeutics.
Montigen Pharmaceuticals
Position: Founder and former scientific leader.
Focus: Drug discovery and early-stage pharmaceutical research.
SuperGen Inc.
Position: Former scientific leader and Chief Scientific Officer.
Focus: Early-stage drug discovery and pharmaceutical development.
Huntsman Cancer Institute, University of Utah
Position: Founding Co-Director of the Center for Investigational Therapeutics and former Associate Professor of Oncological Sciences.
Focus: Translational oncology and experimental cancer treatments.
Brigham Young University
Position: Former Associate Professor of Physiology and Developmental Biology.
Focus: Biomedical research, teaching, and scientific education.

dmg events
dmg events